Evidence map›Paper›PMID 28134246›Full record

ArticleScientific reports2017

Discovery of a junctional epitope antibody that stabilizes IL-6 and gp80 protein:protein interaction and modulates its downstream signaling.

Ralph Adams, Rebecca J Burnley, Chiara R Valenzano, Omar Qureshi, Carl Doyle, Simon Lumb, Maria Del Carmen Lopez, Robert Griffin, David McMillan, Richard D Taylor and 10 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Therapeutic potential ofIn silico pharmacology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Frontiers in pharmacology · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. A Molecular Communications System for the Detection of Inflammatory Levels Related to COVID-19 Disease.IEEE transactions on molecular, biological, and multi-scale communications · 2021
    Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 2 countries.

Ralph AdamsNew Medicines, UCB-Celltech, 208 Bath Road, SL1 3WE, Slough UK.
Rebecca J BurnleyNew Medicines, UCB-Celltech, 208 Bath Road, SL1 3WE, Slough UK.
Chiara R ValenzanoNew Medicines, UCB-Celltech, 208 Bath Road, SL1 3WE, Slough UK.
Omar QureshiNew Medicines, UCB-Celltech, 208 Bath Road, SL1 3WE, Slough UK.
Carl DoyleNew Medicines, UCB-Celltech, 208 Bath Road, SL1 3WE, Slough UK.
Simon LumbNew Medicines, UCB-Celltech, 208 Bath Road, SL1 3WE, Slough UK.
Maria Del Carmen LopezNew Medicines, UCB-Celltech, 208 Bath Road, SL1 3WE, Slough UK.
Robert GriffinNew Medicines, UCB-Celltech, 208 Bath Road, SL1 3WE, Slough UK.
David McMillanNew Medicines, UCB-Celltech, 208 Bath Road, SL1 3WE, Slough UK.
Richard D TaylorNew Medicines, UCB-Celltech, 208 Bath Road, SL1 3WE, Slough UK.
Chris MeierNew Medicines, UCB-Celltech, 208 Bath Road, SL1 3WE, Slough UK.
Prashant MoriNew Medicines, UCB-Celltech, 208 Bath Road, SL1 3WE, Slough UK.
Laura M GriffinNew Medicines, UCB-Celltech, 208 Bath Road, SL1 3WE, Slough UK.
Ulrich WerneryCentral Veterinary Research Laboratory, P.O.Box 597, Dubai, United Arab Emirates.
Jörg KinneCentral Veterinary Research Laboratory, P.O.Box 597, Dubai, United Arab Emirates.
Stephen RapeckiNew Medicines, UCB-Celltech, 208 Bath Road, SL1 3WE, Slough UK.
Terry S BakerNew Medicines, UCB-Celltech, 208 Bath Road, SL1 3WE, Slough UK.
Alastair D G LawsonNew Medicines, UCB-Celltech, 208 Bath Road, SL1 3WE, Slough UK.
Michael WrightNew Medicines, UCB-Celltech, 208 Bath Road, SL1 3WE, Slough UK.
Anna EttorreNew Medicines, UCB-Celltech, 208 Bath Road, SL1 3WE, Slough UK.
UCB Pharma (United Kingdom) · GBCentral Veterinary Research Laboratory · AE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein:protein interactions are fundamental in living organism homeostasis. Here we introduce VHH6, a junctional epitope antibody capable of specifically recognizing a neo-epitope when two proteins interact, albeit transiently, to form a complex. Orthogonal biophysical techniques have been used to prove the "junctional epitope" nature of VHH6, a camelid single domain antibody recognizing the IL-6-gp80 complex but not the individual components alone. X-ray crystallography, HDX-MS and SPR analysis confirmed that the CDR regions of VHH6 interact simultaneously with IL-6 and gp80, locking the two proteins together. At the cellular level, VHH6 was able to alter the response of endothelial cells to exogenous IL-6, promoting a sustained STAT3 phosphorylation signal, an accumulation of IL-6 in vesicles and an overall pro-inflammatory phenotype supported further by transcriptomic analysis. Junctional epitope antibodies, like VHH6, not only offer new opportunities in screening and structure-aided drug discovery, but could also be exploited as therapeutics to modulate complex protein:protein interactions.

Indexed as

Epitope MappingAnimalsAntibodiesCamelusCHO CellsCricetulusGene Expression ProfilingHEK293 CellsHumansInterleukin-6PhosphorylationProtein Structure, TertiaryReceptors, Interleukin-6Signal TransductionSTAT3 Transcription FactorAntibodiesInterleukin-6Receptors, Interleukin-6STAT3 Transcription Factor

Identifiers

PMID28134246
PMCPMC5278397
OpenAlexW2580472438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.